Literature DB >> 23182048

The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms.

Bilge Volkan-Salanci1, Hakan Aksoy, Pınar Özgen Kiratli, Erol Tülümen, Nilüfer Güler, Berna Öksüzoglu, Lale Tokgözoğlu, Belkıs Erbaş, Mehmet Alikaşifoğlu.   

Abstract

The aim of this prospective clinical study is to evaluate the relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 (CBR3p.V244M) and glutathione S transferase Pi (GSTP1p.I105V) polymorphisms. Seventy patients with normal cardiac function and no history of cardiac disease scheduled to undergo anthracycline chemotherapy were included in the study. The patients' cardiac function was evaluated by gated blood pool scintigraphy and echocardiography before and after chemotherapy, as well as 1 year following therapy. Gene polymorphisms were genotyped in 70 patients using TaqMan probes, validated by DNA sequencing. A deteriorating trend was observed in both systolic and diastolic parameters from GG to AA in CBR3p.V244M polymorphism. Patients with G-allele carriers of GSTP1p.I105V polymorphism were common (60%), with significantly decreased PFR compared to patiens with AA genotype. Variants of CBR3 and GSTP1 enzymes may be associated with changes in short-term functional cardiac parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182048     DOI: 10.1179/1973947812Y.0000000037

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  12 in total

Review 1.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 2.  Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.

Authors:  Emily A Pinheiro; Tarek Magdy; Paul W Burridge
Journal:  J Cardiovasc Transl Res       Date:  2020-02-20       Impact factor: 4.132

3.  Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.

Authors:  Bryan P Schneider; Fei Shen; Laura Gardner; Milan Radovich; Lang Li; Kathy D Miller; Guanglong Jiang; Dongbing Lai; Anne O'Neill; Joseph A Sparano; Nancy E Davidson; David Cameron; Irmina Gradus-Pizlo; Ronald A Mastouri; Thomas M Suter; Tatiana Foroud; George W Sledge
Journal:  Clin Cancer Res       Date:  2016-12-19       Impact factor: 12.531

Review 4.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

Review 5.  hiPSCs in cardio-oncology: deciphering the genomics.

Authors:  Emily A Pinheiro; K Ashley Fetterman; Paul W Burridge
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 6.  Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: a scoping review.

Authors:  Irene Cartas-Espinel; Marcelino Telechea-Fernández; Carlos Manterola Delgado; Andrés Ávila Barrera; Nicolás Saavedra Cuevas; Angela L Riffo-Campos
Journal:  ESC Heart Fail       Date:  2022-03-08

Review 7.  Genetics of Anthracycline-Associated Cardiotoxicity.

Authors:  Talal Khalid Al-Otaibi; Benjamin Weitzman; Usman A Tahir; Aarti Asnani
Journal:  Front Cardiovasc Med       Date:  2022-04-21

8.  Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.

Authors:  Siew Lian Leong; Nathorn Chaiyakunapruk; Shaun Wen Huey Lee
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

9.  Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Yang; Guoping Li; Manke Guan; Aneesh Bapat; Qianqian Dai; Changming Zhong; Tao Yang; Changyong Luo; Na An; Wenjing Liu; Fan Yang; Haie Pan; Pengqian Wang; Yonghong Gao; Ye Gong; Saumya Das; Hongcai Shang; Yanwei Xing
Journal:  Front Cardiovasc Med       Date:  2021-06-04

10.  A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Amit P Bhavsar; Henk Visscher; Shahrad R Rassekh; Yuling Li; Jong W Lee; Liam R Brunham; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Ursula Amstutz; Michael J Rieder; Daniel Bernstein; Bruce C Carleton; Michael R Hayden; Colin J D Ross
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.